Statement of Principles concerning malignant neoplasm of unknown primary site (Reasonable Hypothesis) (No. 103 of 2022)

The central concept is the reasonable hypothesis, a standard of proof unique to veterans’ compensation law under the VEA. It is lower than the civil balance of probabilities; the hypothesis need only be plausible and consistent with the known medical‑scientific evidence. The SoP declares that the identified factors, if present and service‑related, are sufficient to raise that hypothesis. The decision‑maker cannot reject the claim on the basis that the hypothesis is not the most probable explanation. Sound medical‑scientific evidence is the foundation the Repatriation Medical Authority claims underpins the factors (section 8). That claim is a statement of the Authority’s view, not a finding of fact. It can be tested in judicial review but is generally given deference. Clinical onset is a crucial temporal trigger: every factor in section 9 is anchored to the date the CUP first became clinically apparent. The factor must have operated before that onset (or, for inability to obtain appropriate clinical management, before a material contribution to an existing condition). The SoP imposes minimum latency periods (e.g., smoking must have commenced at least five years before onset) and post‑cessation windows (e.g., onset within 20 years of ceasing smoking, 40 years for alcohol). Cumulative equivalent dose of ionising radiation is a technical quantity calculated under a 2017 ARPANSA guide; it includes both external and internal exposure excluding normal background. The threshold is 0.1 sievert to at least one body location. This is a relatively low dose - equivalent to about 10 CT scans of a single organ - and may be met by medical imaging during service, nuclear exposure, or aircrew cosmic radiation. Pack‑year and kilogram of alcohol are quantitative thresholds requiring careful computation. Alcohol is measured in standard drinks of 10 grams. The SoP also defines specified human papillomavirus as types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 70, 73 and 82 - a wider list than just the high‑risk types commonly tested. Processed meat product includes transformed meat (ham, salami, bacon) and the factor applies only to adenocarcinoma of unknown primary site, requiring average intake of at least 25 grams per day for five consecutive years in the 20 years before onset. The SoP also defines terminal event (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function) for death claims.

The primary class affected is current and former members of the Australian Defence Force who have rendered relevant service as defined in the dictionary - that is, operational service, peacekeeping service, hazardous service, or British nuclear test defence service under the VEA, or warlike or non‑warlike service under the MRCA. Their dependants are also affected in death claims. The instrument directly binds the Department of Veterans’ Affairs (DVA) and its delegates, who must apply its terms when assessing claims for pension or compensation for CUP. It also affects the Veterans’ Review Board, the Administrative Appeals Tribunal and the courts, which review decisions under the VEA and MRCA and must give effect to the SoP as a legislative instrument. Medical practitioners, particularly pathologists, oncologists and radiation oncologists, are indirectly affected because their reports - especially histological confirmation, exclusion of primary site, HPV typing, dose reconstruction and dietary history - become determinative of eligibility. Lawyers and advocates who represent claimants need to understand the quantitative thresholds and the temporal rules to frame effective submissions. The SoP also has a broader fiscal impact on the Commonwealth and ultimately on taxpayers, because each factor that is met and related to service potentially converts a non‑compensable disease into a compensable one, increasing the liability of the Military Rehabilitation and Compensation Scheme and the Veterans’ Entitlements scheme. The Repatriation Medical Authority itself is affected in that it must defend its determination if challenged. The instrument also affects future SoPs: section 11 creates a chain of presumptions by incorporating other SoPs for conditions like diabetes, HPV infection and Epstein‑Barr virus infection, thereby widening the net of potential service‑connection.

Claimants have the right to have their CUP claim assessed using the factors in section 9, provided the definition in section 7(2) is met. That right is procedural: the decision‑maker must consider whether any factor exists and is related to service. If at least one factor is established, the claimant gains a significant evidentiary advantage - the onus shifts to DVA to disprove the connection. The claimant’s corresponding duty is to produce evidence that satisfies the precise quantitative and temporal requirements. For smoking, that means proving at least 10 pack‑years, with commencement at least five years before clinical onset, and, if smoking ceased before onset, that onset occurred within 20 years of cessation. For alcohol, the duty is to prove at least 200 kilograms consumed, with similar latency and a 40‑year cessation window. For ionising radiation, the claimant must produce a dose reconstruction or medical records showing cumulative equivalent dose of at least 0.1 sievert to a body location, at least five years before onset. For the HPV factors, the claimant must provide histology or PCR results showing infection with the specified types. For the processed meat factor (adenocarcinoma only), the claimant must document average daily intake over a five‑year period within the 20 years before onset. The duty to relate the factor to service under section 10 is not defined in the SoP, but generally requires showing that the factor arose out of, or was contributed to by, the person’s service - for example, smoking that started or increased due to operational stress, or diagnostic radiation received during service. DVA’s duty is to apply the SoP strictly; it may not impose additional evidential requirements beyond those stated. DVA also has a duty under section 10(2): the factor in section 9(9) (inability to obtain appropriate clinical management) applies only to material contribution or aggravation, not to initial causation, so DVA must not improperly apply that factor to a claim where the CUP arose before or during service but not out of service. DVA retains the right to reject a claim if no factor exists, if the factor is not related to service, or if the contrary is proved to the required standard.

The SoP itself does not create penalties; it is a rule of entitlement, not a penal instrument. Enforcement of the compensation regime occurs through the claims process and, indirectly, through the general law. A claimant who knowingly provides false information to establish a factor - for example, fabricating a smoking history or falsifying radiation exposure records - commits an offence under the Criminal Code 1995 (Cth) for obtaining a financial advantage by deception. The maximum penalty for such an offence is 10 years imprisonment. DVA also has administrative remedies: it can recover overpayments and may refer cases to the Commonwealth Director of Public Prosecutions. The SoP also imposes an evidentiary penalty on claimants who cannot meet the thresholds: they simply receive no compensation for CUP. There is no penalty for failing to prove a factor; that is simply the end of the claim. The real penalty is borne by the Commonwealth if the thresholds are set too low, because then many service‑related claims that might be weak on causation will succeed. The SoP itself cannot be directly challenged as a penalty, but if a decision‑maker misapplies it - for instance, accepting a factor without proper evidence or misinterpreting the cessation windows - that decision can be set aside on review. The Repatriation Medical Authority is not subject to enforcement under this instrument; its determination of factors is quasi‑legislative and reviewable only on narrow grounds of jurisdictional error or lack of sound medical‑scientific evidence.

The instrument is made under section 196B(2) of the VEA, and its operation is confined to claims under sections 120A of the VEA and 338 of the MRCA. It repeals and replaces the earlier CUP SoP No. 80 of 2014, so claims determined after 21 November 2022 must be assessed under this new version. The SoP does not apply to claims under the Safety, Rehabilitation and Compensation (Defence‑related Claims) Act 1988 or any state workers’ compensation scheme. It also interacts with other SoPs through section 11: if a factor in this SoP refers to an injury or disease that itself has a SoP under subsection 196B(2), that other SoP applies as in force from time to time. For example, factor 7 is “having diabetes mellitus before the clinical onset”. Diabetes mellitus is covered by its own SoP; to satisfy factor 7, the claimant must not only prove they had diabetes before the CUP onset, but also that the diabetes is itself related to service under the diabetes SoP. This creates a cascading set of presumptions that can be either helpful or burdensome for claimants depending on the strength of their service connection. The SoP also references the ICD‑10‑AM code C80 but provides its own definition that controls, so a diagnosis with that code is not determinative; the clinical criteria in section 7(2) must be met. For the ionising radiation factor, the SoP incorporates the ARPANSA Guide to calculation of cumulative equivalent dose as in force on 2 August 2017. That guide is not reproduced in the instrument, so claimants must locate and apply that separate document. The instrument does not override or amend the VEA or MRCA; it operates within their existing framework. It also does not affect any tort‑based claim a veteran might bring against a third party, but compensation from such a claim may be taken into account under the compensation recovery provisions of the MRCA and VEA.

The SoP itself has no amendment history within the source text; it is the initial version of No. 103 of 2022. Its only relevant history is that it repeals the earlier Statement of Principles concerning malignant neoplasm of unknown primary site No. 80 of 2014 (Federal Register of Legislation No. F2014L01142). That earlier SoP was made under both subsections 196B(2) and (8) of the VEA, meaning it covered both the reasonable hypothesis standard and the balance of probabilities standard. The new SoP is made only under subsection 196B(2), so it applies only to claims where the reasonable hypothesis standard is relevant (i.e., operational service, warlike service, etc.). Claims that require the balance of probabilities standard (e.g., for malignant neoplasm of unknown primary site arising out of defence service that is not operational) may no longer have a dedicated SoP, though the general law would apply. The commencement date is 21 November 2022. No further amendments are recorded in the instrument. The repeal of the 2014 SoP may have been prompted by changes in medical‑scientific evidence (e.g., stronger evidence linking alcohol, processed meat, or HPV to CUP), but the source does not state reasons. The instrument also differs from its predecessor in the specific factors listed; notably, the new SoP includes consumption of alcohol (200 kg) and processed meat (25g/day for adenocarcinoma) and the inability to obtain appropriate clinical management factor, which were likely not present in the 2014 version. The removal of the subsection 196B(8) basis suggests a deliberate narrowing of the instrument’s scope.

The source does not refer to any litigation, and the SoP is relatively new (commenced November 2022). No cases interpreting this specific instrument are likely to exist yet. However, litigation is foreseeable around several provisions. The definition of “appropriate diagnostic investigations” in section 7(2)(a) is undefined and could be contested: what investigations are appropriate will vary with clinical practice and resource availability. The “inability to obtain appropriate clinical management” factor in section 9(9) is vague and likely to be litigated, particularly as to what constitutes “appropriate” management and whether the inability must have been due to service circumstances (e.g., remote posting, DVA refusal) or could be due to personal choice. The temporal calculations for pack‑years and alcohol consumption will generate disputes over the reliability of self‑reported histories. The ionising radiation factor’s reference to a 2017 ARPANSA guide may become outdated, leading to challenges about its continuing validity. The exclusion of haematolymphoid tumours, melanoma and mesenchymal tumours may be litigated if a tumour is misclassified or if the line between these excluded types and CUP is blurred. The interaction with other SoPs under section 11 could also be litigated if the diabetes or HPV SoPs themselves are unclear or under challenge. In the broader context, the High Court has considered the constitutional validity of the SoP framework in Repatriation Commission v Smith (2000) 174 ALR 321, but that was not about this particular SoP. Practitioners should expect that the DVA will test the boundaries of the new factors, especially the alcohol and processed meat thresholds, in the Veterans’ Review Board and the Administrative Appeals Tribunal.

Several provisions in the SoP are less generous than they first appear. The smoking factor requires a minimum of 10 pack‑years; a veteran who smoked 9.5 pack‑years fails, no matter how heavy the duration. The cessation window is strict: if a veteran quit smoking 21 years before onset, the factor is not met even if they smoked 50 pack‑years. Similarly for alcohol, the 40‑year window after cessation means many older veterans will fall outside it. The ionising radiation threshold of 0.1 sievert cumulative equivalent dose may seem low, but the dose must be calculated to a specific organ or tissue, not whole‑body average, and must exclude normal background. Many routine diagnostic exposures (e.g., chest X‑rays) contribute only microsieverts; even a single CT scan is about 5-10 mSv (0.005-0.01 Sv). To reach 0.1 Sv, a veteran would need about 10 CT scans of the same body region, or prolonged occupational exposure. Proving that requires detailed records and expert dose reconstruction. The HPV factor in section 9(4) is only for squamous cell carcinoma of unknown primary site of the head and neck and only for HPV types 16 or 18. Other high‑risk HPV types (e.g., 31, 33, 45) are specified in section 9(5) but only for squamous cell carcinoma involving the inguinal lymph nodes. A veteran with SCC of a neck node from HPV 31 cannot use factor 4; they would need to rely on another factor like smoking or alcohol. The processed meat factor only applies to adenocarcinoma of unknown primary site. If the histology is poorly differentiated or undifferentiated, it may not qualify as adenocarcinoma, and then the factor cannot be used. The “inability to obtain appropriate clinical management” factor in section 9(9) appears broad, but section 10(2) limits it to material contribution or aggravation only; it cannot be used to establish the initial onset of CUP. That means the disease must have already existed before the inability arose. Terminal event definitions are inclusive but not exhaustive: only five causes are listed, so a death from, say, pulmonary embolism contributed to by CUP might not fit unless it is classified as circulatory failure. The dictionary definition of “one pack‑year” uses 20 cigarettes per day, but many veterans smoked roll‑your‑own or different sized cigars; the note says 1 gram of tobacco equals one cigarette, which is a rough conversion and may be disputed. The alcohol calculation uses Australian standard drinks of 10 grams; but veterans may have consumed beverages with different alcohol content, requiring careful estimation.

For legal practitioners and advocates managing a CUP claim, compliance with the SoP requires a methodical, evidence‑driven approach. First, confirm the veteran has relevant service as defined in the dictionary - operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, or warlike/non‑warlike service under the MRCA. Then, obtain the full medical records to verify that the condition meets the definition in section 7(2): a histologically confirmed metastatic malignancy, with the primary site unidentified after a complete history, physical examination and appropriate investigations. The pathology report must explicitly state that haematolymphoid tumours, melanoma and mesenchymal tumours have been excluded. If the histology is not clear, request immunohistochemistry to rule out those excluded types. Next, document the clinical onset date from the medical file - the date when the condition first became symptomatic or was diagnosed. That date anchors all the factor windows. For each potential factor in section 9, gather evidence of the qualifying event: an accurate smoking history (pack‑years calculated by dividing cigarettes per day by 20 and multiplying by years smoked; include start and quit dates), alcohol consumption history (total grams of alcohol, using 10g per standard drink, and dates), radiation exposure records (occupational dosimetry, medical imaging records, service in nuclear test areas), HPV or EBV test results (PCR or immunohistochemistry on biopsy material), diabetes diagnosis date, and dietary history for processed meat. For the processed meat factor (adenocarcinoma only), the evidence must show an average of at least 25 grams per day for at least five consecutive years within the 20 years before onset. Maintain contemporaneous records where possible; self‑reports are admissible but less persuasive. For each factor, check the latency and cessation windows: the factor must have commenced at least five years before onset (except diabetes and inability to obtain clinical management, which have no minimum latency), and if exposure ceased, the onset must fall within the prescribed post‑cessation period. The factor must be related to service under section 10: prepare a statement linking the factor to service activities - e.g., smoking due to stress on operational service, diagnostic radiation from a combat injury, HPV infection from consensual sexual contact that occurred during service leave (but note that this may be difficult to prove). If relying on inability to obtain appropriate clinical management, document the specific management that was unavailable (e.g., chemotherapy, radiotherapy, surgical referral) and show that this contributed to a progression or aggravation of an existing CUP. Also, check if any factor refers to another disease (e.g., diabetes) and ensure that disease’s SoP is also satisfied and linked to service. Finally, prepare a clear submission mapping each factor to the evidence, and file the claim with the DVA. Keep abreast of any decisions from the Veterans’ Review Board or AAT interpreting the new factors, as the instrument will be litigated over time.